Bacterial consortium therapy for prevention of recurrent c difficile infection
JAMA
About The Study: Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with one or more prior CDI episodes in the last six months and those with primary CDI at high risk for recurrence, high-dose VE303 (a novel oral microbiome-directed therapy composed of nonpathogenic, nontoxigenic, commensal strains of Clostridia) prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.
Authors: Jeffrey L. Silber, M.D., of Vedanta Biosciences Inc., in Cambridge, Massachusetts, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.4314)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: The study is being released to coincide with presentation at the European Congress of Clinical Microbiology & Infectious Diseases.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.4314?guestAccessKey=78cc89bf-06db-4687-a463-da021a5f18dd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=041523
END
Authors: Jeffrey L. Silber, M.D., of Vedanta Biosciences Inc., in Cambridge, Massachusetts, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.4314)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: The study is being released to coincide with presentation at the European Congress of Clinical Microbiology & Infectious Diseases.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.4314?guestAccessKey=78cc89bf-06db-4687-a463-da021a5f18dd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=041523
END